Sirolimus dosage during and after conversion from calcineurin inhibitor therapy to sirolimus in chronic kidney transplant patients

Kidney and Blood Pressure Research

Volumn 27, Issue 3, 2004, Pages 186-190

  Diekmann, Fritz ^a   Fritsche, Lutz ^a   Neumayer, Hans Hellmut ^a   Budde, Klemens ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Calcineurin inhibitor; Kidney transplant; Rapamycin; Sirolimus

Indexed keywords

CALCINEURIN INHIBITOR; RAPAMYCIN;

ADULT; AGED; ANEMIA; BRONCHIOLITIS; CHRONIC DISEASE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONFERENCE PAPER; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE REGIMEN; DYSLIPIDEMIA; EPISTAXIS; FEMALE; GRAFT FAILURE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MAINTENANCE DRUG DOSE; MALE; PRIORITY JOURNAL; STOMATITIS; SURGICAL PATIENT; SURVIVAL; SURVIVAL RATE; TIME;

CALCINEURIN; CHRONIC DISEASE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; PROSPECTIVE STUDIES; SIROLIMUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 4344665637     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000079809     Document Type: Conference Paper

References (10)

1. Diekmann F, Waiser J, Fritsche L, Dragun D, Neumayer HH, Budde K: Conversion to rapamycin in renal allograft recipients with biopsyproven calcineurin inhibitor-induced nephrotoxicity. Transplant Proc 2001;33:3234-3235.
2. Dominguez J, Mahalati K, Kiberd B, McAlister VC, MacDonald AS: Conversion to rapamycin immunosuppression in renal transplant recipients: Report of an initial experience. Transplantation 2000;70:1244-1247.
3. Sehgal SN, Molnar-Kimber K, Okain TD, Weichman BO: Rapamycin: A novel immunosuppressive macrolide. Med Res Rev 1994;14:1-22.
4. Nankivell BJ, Fenton-Lee CA, Kuypers DR, Cheung E, Allen RD, O'Connell PJ, Chapman JR: Effect of histological damage on long-term kidney transplant outcome. Transplantation 2001;71:515-523.
5. Solez K, Vincenti F, Filo RS: Histopathologic findings from 2-year protocol biopsies from a US multicenter kidney transplant trial comparing tarolimus versus cyclosporine: A report of the FK506 Kidney Transplant Study Group. Transplantation 1998;66:1736-1740.
6. Groth CG, Backman L, Morales JM, Calne R, Kreis H, Lang P, Touraine JL, Claesson K, Campistol JM, Durand D, Wramner L, Brattstrom C, Charpentier B: Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999;67:1036-1042.
7. Morales JM, Wramner L, Kreis H, Durand D, Campistol JM, Andres A, Arenas J, Negre E, Burke JT, Groth CG, Sirolimus European Renal Transplant Study Group, et al: Sirolimus European Renal Transplant Study Group: Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant 2002;2:436-442.
8. Oberbauer R, Kreis H, Johnson RW, Mota A, Claesson K, Ruiz JC, Wilczek H, Jamieson N, Henriques AC, Paczek L, Chapman J, Burke JT: Rapamune Maintenance Regimen Study Group. Transplantation 2003;76:364-370.
9. Van Gelder T, ter Meulen CG, Hené R, Weimar W, Hoitsma A: Oral ulcers in kidney transplant recipients treated with Sirolimus and mycophenolate mofetil. Transplantation 2003;75:788-791.
10. Morelon E, Stern M, Israel-Biet D, Correas JM, Danel C, Mamzer-Bruneel MF, Peraldi MN, Kreis H: Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients. Transplantation 2001;72:787-797.